ABSTRACT
Stress elicits a variety of autonomic responses, including hyperthermia (stress fever) in humans and animals. In this present study, we investigated the circuit basis for thermogenesis and heat conservation during this response. We first demonstrated the glutamatergic identity of the dorsal hypothalamic area (DHAVglut2) neurons that innervate the raphe pallidus nucleus (RPa) to regulate core temperature (Tc) and mediate stress-induced hyperthermia. Then, using chemogenetic and optogenetic methods to manipulate this hypothalamomedullary circuit, we found that activation of DHAVglut2 neurons potently drove an increase in Tc, but surprisingly, stress-induced hyperthermia was only reduced by about one-third when they were inhibited. Further investigation showed that DHAVglut2 neurons activate brown adipose tissue (BAT) but do not cause vasoconstriction, instead allowing reflex tail artery vasodilation as a response to BAT-induced hyperthermia. Retrograde rabies virus tracing revealed projections from DHAVglut2 neurons to RPaVglut3, but not to RPaGABA neurons, and identified a set of inputs to DHAVglut2 â RPa neurons that are likely to mediate BAT activation. The dissociation of the DHAVglut2 thermogenic pathway from the thermoregulatory vasoconstriction (heat-conserving) pathway may explain stress flushing (skin vasodilation but a feeling of being too hot) during stressful times.
Subject(s)
Body Temperature Regulation/physiology , Fever/physiopathology , Hypothalamus/metabolism , Neurons/physiology , Thermogenesis , Animals , Female , Male , Mice , Nucleus Raphe Pallidus/physiology , Optogenetics , Stress, PhysiologicalABSTRACT
Sympathetic premotor neurons of the paraventricular hypothalamus (PVN) play a role in hemodynamics adjustments during changes in body fluid homeostasis. However, PVN contribution to the tonic control of cardiac function remains to be systematically studied. In this study, we assessed whether GABAergic and adrenergic synapses, known for being active in the PVN, are involved in the control of cardiac function. Adult male Wistar rats (250-350 g; n = 27) were anesthetized with urethane (1.2-1.4 g/kg i.p.) and underwent catheterization of femoral artery to record blood pressure and heart rate. The femoral vein was used to inject the vasoactive agents phenylephrine (10 µg/kg) and sodium nitroprusside (10 µg/kg) and to supplement anesthesia. The cardiac left ventricle was catheterized to record left ventricular pressure and its derivative. Craniotomy allowed for injections (100 nL) into the PVN of: muscimol (20 mM), bicuculline methiodide (0.4 mM), propranolol (10 mM), isoproterenol (100 µM), phentolamine (13 mM), phenylephrine (30 nM). We found that: (i) inhibition of PVN by muscimol, reduced arterial pressure, cardiac chronotropy and inotropy; (ii) disinhibition of PVN neurons by bicuculline evoked positive chronotropy and inotropy, and increase blood pressure; (iii) PVN alpha adrenergic receptors control cardiac chronotropy and inotropy; (iv) beta adrenergic receptors of the PVN do not influence cardiac function; (v) afterload does not contribute to the PVN-evoked inotropy. Our results indicate that the modulation of the activity of PVN neurons exerted by GABAergic and adrenergic mechanisms contribute to the control of cardiac function.
ABSTRACT
The intermediate region of the posterior insular cortex (intermediate IC) mediates sympathoexcitatory responses to the heart and kidneys. Previous studies support hypertension-evoked changes to the structure and function of neurons, blood vessels, astrocytes and microglia, disrupting the organization of the neurovascular unit (NVU). In this study, we evaluated the functional and anatomical integrity of the NVU at the intermediate IC in the spontaneously hypertensive rat (SHR) and its control the Wistar-Kyoto (WKY). Under urethane anesthesia, NMDA microinjection (0.2 mmol/L/100 nL) was performed at the intermediate IC with simultaneous recording of renal sympathetic nerve activity (RSNA), heart rate (HR) and mean arterial pressure (MAP). Alterations in NVU structure were investigated by immunofluorescence for NMDA receptors (NR1), blood vessels (70 kDa FITC-dextran), astrocytes (GFAP), and microglia (Iba1). Injections of NMDA into intermediate IC of SHR evoked higher amplitude responses of RSNA, MAP, and HR On the other hand, NMDA receptor blockade decreased baseline RSNA, MAP and HR in SHR, with no changes in WKY Immunofluorescence data from SHR intermediate IC showed increased NMDA receptor density, contributing to the SHR enhanced sympathetic responses, and increased in vascular density (increased number of branches and endpoints, reduced average branch length), suggesting angiogenesis. Additionally, IC from SHR presented increased GFAP immunoreactivity and contact between astrocyte processes and blood vessels. In SHR, IC microglia skeleton analysis supports their activation (reduced number of branches, junctions, endpoints and process length), suggesting an inflammatory process in this region. These findings indicate that neurogenic hypertension in SHR is accompanied by marked alterations to the NVU within the IC and enhanced NMDA-mediated sympathoexcitatory responses likely contributors of the maintenance of hypertension.
Subject(s)
Cerebral Cortex/physiology , Hypertension/physiopathology , Kidney/innervation , Neurovascular Coupling/physiology , Sympathetic Nervous System/physiology , Animals , Arterial Pressure/drug effects , Arterial Pressure/physiology , Astrocytes/metabolism , Cerebral Cortex/drug effects , Excitatory Amino Acid Agonists/pharmacology , Glial Fibrillary Acidic Protein/metabolism , Heart Rate/drug effects , Heart Rate/physiology , N-Methylaspartate/pharmacology , Neurovascular Coupling/drug effects , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Sympathetic Nervous System/drug effectsABSTRACT
BACKGROUND: Liposomes are concentric lipid vesicles that allow a sustained release of entrapped substances. GABA (γ-aminobutyric acid) is the most prevalent inhibitory neurotransmitter in the central nervous system. NEW METHOD: Using GABA-containing liposomes (GL) prepared by the freeze-thawing method, we determined the effect of sustained release of GABA on expression of neuronal nitric oxide synthase (nNOS) and GABAA receptor (GABAAR) in an in vitro neuronal model. RESULTS: Neuronal cell line NG108-15 treated with different doses of GL during 24h showed an increase in expression of GABAAR (54 and 50% with 10 and 20ng doses, respectively) and nNOS (138, 157 and 165% with 20, 50 and 100ng doses, respectively) compared with cells treated with empty liposomes (EL). Additionally, cells treated with 50ng of GL showed an increase in GABAAR (23%) after 1h followed by an increase in nNOS (55, 46 and 55%) at 8, 12 and 24h time points, respectively. Immunofluorescence experiments confirmed an increase in nNOS (134%) and basal intracellular levels of nitric oxide (84%) after GL treatment. Further, treatment of cells with GL showed a decrease in expression of a protein inhibitor of nNOS (PIN) (26, 66 and 57% with 20, 50 and 100ng doses respectively) compared with control. COMPARISON WITH EXISTING METHODS: This is first demonstration for the development of GL that allows sustained slow release of this neurotransmitter. CONCLUSION: These results suggest that a slow release of GABA can change the expression of nNOS possibly via alteration in PIN levels in neuronal cells.
Subject(s)
Gene Expression Regulation, Neoplastic/drug effects , Liposomes/administration & dosage , Nitric Oxide Synthase Type I/metabolism , gamma-Aminobutyric Acid/administration & dosage , Animals , CREB-Binding Protein/metabolism , Cell Line, Tumor , Cytoplasmic Dyneins/metabolism , Dose-Response Relationship, Drug , Drug Delivery Systems , Glutamic Acid/pharmacology , Liposomes/pharmacology , Mice , Neuroblastoma/pathology , Nitrites/metabolism , RNA, Small Interfering/pharmacology , Rats , Receptors, GABA-A/metabolism , Time Factors , gamma-Aminobutyric Acid/pharmacologyABSTRACT
A low resting heart rate (HR) would be of great benefit in cardiovascular diseases. Ivabradine-a novel selective inhibitor of hyperpolarization-activated cyclic nucleotide gated (HCN) channels- has emerged as a promising HR lowering drug. Its effects on the autonomic HR control are little known. This study assessed the effects of chronic treatment with ivabradine on the modulatory, reflex and tonic cardiovascular autonomic control and on the renal sympathetic nerve activity (RSNA). Male Wistar rats were divided in 2 groups, receiving intraperitoneal injections of vehicle (VEH) or ivabradine (IVA) during 7 or 8 consecutive days. Rats were submitted to vessels cannulation to perform arterial blood pressure (AP) and HR recordings in freely moving rats. Time series of resting pulse interval and systolic AP were used to measure cardiovascular variability parameters. We also assessed the baroreflex, chemoreflex and the Bezold-Jarish reflex sensitivities. To better evaluate the effects of ivabradine on the autonomic control of the heart, we performed sympathetic and vagal autonomic blockade. As expected, ivabradine-treated rats showed a lower resting (VEH: 362 ± 16 bpm vs. IVA: 260 ± 14 bpm, p = 0.0005) and intrinsic HR (VEH: 369 ± 9 bpm vs. IVA: 326 ± 11 bpm, p = 0.0146). However, the chronic treatment with ivabradine did not change normalized HR spectral parameters LF (nu) (VEH: 24.2 ± 4.6 vs. IVA: 29.8 ± 6.4; p > 0.05); HF (nu) (VEH: 75.1 ± 3.7 vs. IVA: 69.2 ± 5.8; p > 0.05), any cardiovascular reflexes, neither the tonic autonomic control of the HR (tonic sympathovagal index; VEH: 0.91± 0.02 vs. IVA: 0.88 ± 0.03, p = 0.3494). We performed the AP, HR and RSNA recordings in urethane-anesthetized rats. The chronic treatment with ivabradine reduced the resting HR (VEH: 364 ± 12 bpm vs. IVA: 207 ± 11 bpm, p < 0.0001), without affecting RSNA (VEH: 117 ± 16 vs. IVA: 120 ± 9 spikes/s, p = 0.9100) and mean arterial pressure (VEH: 70 ± 4 vs. IVA: 77 ± 6 mmHg, p = 0.3293). Our results suggest that, in health rats, the long-term treatment with ivabradine directly reduces the HR without changing the RSNA modulation and the reflex and tonic autonomic control of the heart.
ABSTRACT
Angiotensin-(ANG)-(1-7) is known by its central and peripheral actions, which mainly oppose the deleterious effects induced by accumulation of ANG II during pathophysiological conditions. In the present study we evaluated whether a chronic increase in ANG-(1-7) levels in the brain would modify the progression of hypertension. After DOCA-salt hypertension was induced for seven days, Sprague-Dawley rats were subjected to 14 days of intracerebroventricular (ICV) infusion of ANG-(1-7) (200 ng/h, DOCA-A7) or 0.9% sterile saline. As expected, on the 21st day, DOCA rats presented increased mean arterial pressure (MAP) (≈40%), and impaired baroreflex control of heart rate (HR) and baroreflex renal sympathetic nerve activity (RSNA) in comparison with that in normotensive control rats (CTL). These changes were followed by an overactivity of the cardiac sympathetic tone and reduction of the cardiac parasympathetic tone, and exaggerated mRNA expression of collagen type I (≈9-fold) in the left ventricle. In contrast, DOCA rats treated with ANG-(1-7) ICV had an improvement of baroreflex control of HR, which was even higher than that in CTL, and a restoration of the baroreflex control of RSNA, the balance of cardiac autonomic tone, and normalized mRNA expression of collagen type I in the left ventricle. Furthermore, DOCA-A7 had MAP lowered significantly. These effects were not accompanied by significant circulating or cardiac changes in angiotensin levels. Taken together, our data show that chronic increase in ANG-(1-7) in the brain attenuates the development of DOCA-salt hypertension, highlighting the importance of this peptide in the brain for the treatment of cardiovascular diseases.
Subject(s)
Angiotensin I/administration & dosage , Antihypertensive Agents/administration & dosage , Blood Pressure/drug effects , Brain/drug effects , Desoxycorticosterone , Hypertension/prevention & control , Peptide Fragments/administration & dosage , Angiotensin I/blood , Angiotensin II/blood , Animals , Antihypertensive Agents/blood , Baroreflex/drug effects , Brain/metabolism , Brain/physiopathology , Collagen Type I/genetics , Collagen Type III/genetics , Disease Models, Animal , Heart Rate/drug effects , Heart Ventricles/drug effects , Heart Ventricles/metabolism , Heart Ventricles/physiopathology , Hypertension/chemically induced , Hypertension/metabolism , Hypertension/physiopathology , Infusions, Intraventricular , Kidney/innervation , Lateral Ventricles , Male , Peptide Fragments/blood , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Sympathetic Nervous System/drug effects , Sympathetic Nervous System/physiopathology , Time FactorsABSTRACT
This paper describes an experimental approach based on nanotechnology for assessing the chronic actions of short-lived neuropeptides at specific sites of the brain. This methodology combines the advantages of two different techniques: the microinjection of a suspension of peptide-containing liposomes into a specific site of the brain, and the use of liposomes as a local and sustained release nanosystem of the peptide.
Subject(s)
Liposomes/chemistry , Microinjections/methods , Neuropeptides/chemistry , Neuropeptides/metabolism , Animals , Brain/metabolism , Neuropeptides/administration & dosage , RatsSubject(s)
Blood Pressure , Hypertension/physiopathology , Kidney/physiopathology , Renin-Angiotensin System , Stress, Psychological/physiopathology , Sympathetic Nervous System/physiopathology , Animals , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Humans , Hypertension/drug therapy , Hypertension/metabolism , Kidney/innervation , Kidney/metabolism , Renin-Angiotensin System/drug effects , Stress, Psychological/metabolism , Sympathetic Nervous System/drug effects , Sympathetic Nervous System/metabolism , Treatment OutcomeABSTRACT
The main objective of the present study was to evaluate baroreceptor control of heart rate (HR) and renal sympathetic nerve activity (RSNA) in transgenic rats (TG) with low angiotensinogen production in glial cells, TGR(ASrAogen)-680. In addition, the sympathetic and vagal autonomic tonus to the heart was investigated. As previously shown, TG rats presented a lower arterial pressure (AP) and HR. However, TG rats had decreased AP variability during the night (8.9+/-0.4 mmHg vs 9.8+/-0.3 mmHg, in SD) accompanied by an increase in HR variability (39+/-1 beats/min vs 35+/-1 beats/min, in SD) and augmented locomotor activity during the night (3.5+/-0.3 counts/min vs 2.5+/-0.2 counts/min, in SD). In addition, TG rats presented increased baroreflex sensitivity for the RSNA (slope of line that correlates decreases in RSNA and increases in AP=1.36+/-0.18 vs 0.77+/-0.1, in SD) and an increased sensitivity for both the baroreflex bradycardia (0.79+/-0.04 ms/mmHg vs 0.52+/-0.04 ms/mmHg, in SD) and tachycardia (1.46+/-0.1 ms/mmHg vs 0.93+/-0.01 ms/mmHg, in SD). Further, TG rats had increased vagal tonus (25+/-3 beats/min vs 11+/-4 beats/min in SD) without significant change in the sympathetic tonus to the heart. These results confirm and extend previous observations showing that glial angiotensinogen, the main source of brain RAS peptides, importantly modulates sympathetic tonus, at least to the renal nerve, and vagal tonus to the heart.
Subject(s)
Angiotensinogen/physiology , Baroreflex/physiology , Heart Rate/physiology , Kidney/innervation , Sympathetic Nervous System/physiology , Angiotensinogen/genetics , Animals , Animals, Genetically Modified , Blood Pressure/physiology , Brain/physiology , Heart/innervation , Neuroglia/physiology , Rats , Rats, Sprague-Dawley , Telemetry , Vagus Nerve/physiologyABSTRACT
Microinjection of the neuronal inhibitor muscimol into the midbrain lateral/dorsolateral periaqueductal gray (l/dlPAG) suppresses increases in heart rate (HR) and mean arterial pressure (MAP) evoked by microinjection of the GABA(A) receptor antagonist bicuculline methiodide (BMI) into the dorsomedial hypothalamus (DMH) in rats. Injection of BMI into the DMH also increases body temperature (Tco) and motor activity. Here, our goal was to extend previous findings by examining the effect of microinjection of muscimol into the PAG on these thermogenic and behavioral responses in conscious freely moving rats. Microinjection of muscimol (300 pmol and 1 nmol) alone into the l/dlPAG reduced baseline Tco without affecting activity, HR, or MAP. Similar injection of a dose that failed to alter baseline Tco (100 pmol) suppressed the increases in Tco evoked from the DMH and significantly attenuated DMH-induced increases in locomotor activity. Whereas microinjection of 1 nmol muscimol into the ldlPAG abolished the increases in Tco evoked from the DMH and in fact lowered body temperature to a degree similar to that seen after this dose of muscimol alone, 1 nmol muscimol at adjacent sites outside the targeted region of the PAG had no significant effect on DMH-induced increases in Tco or any other parameter. These results indicate a role for neuronal activity in the l/dlPAG in (1) the temperature and behavioral responses to disinhibition of neurons in the DMH, and (2) the maintenance of basal body temperature in conscious freely moving rats.
Subject(s)
Body Temperature/physiology , Dorsomedial Hypothalamic Nucleus/physiology , Muscimol/pharmacology , Neural Pathways/physiology , Periaqueductal Gray/physiology , Animals , Blood Pressure/drug effects , Blood Pressure/physiology , Body Temperature/drug effects , Body Temperature Regulation/drug effects , Body Temperature Regulation/physiology , Dorsomedial Hypothalamic Nucleus/drug effects , Dose-Response Relationship, Drug , GABA Agonists/pharmacology , Heart Rate/drug effects , Heart Rate/physiology , Male , Motor Activity/drug effects , Motor Activity/physiology , Neural Inhibition/drug effects , Neural Inhibition/physiology , Neural Pathways/drug effects , Neurons/drug effects , Neurons/physiology , Periaqueductal Gray/drug effects , Rats , Synaptic Transmission/drug effects , Synaptic Transmission/physiology , Thermogenesis/drug effects , Thermogenesis/physiology , gamma-Aminobutyric Acid/metabolismABSTRACT
RESUMO: O estresse emocional resulta em ativação de vias específicas do sistema nervoso central, que produzem respostas autonômicas, comportamentais e endócrinas. Sabe-se que situações de estresse recorrentes ou prolongadas podem resultar em vários estados patológicos, como por exemplo, a hipertensão arterial.O Hipotálamo tem papel fundamental na integração das respostas fisiológicas ao estresse emocional. Particularmente, estudos têm mostrado que um núcleo especifico do hipotálamo, o hipotálamo dorsomedial (DMH), é um componente fundamental das vias centrais mediadoras das respostas cardiovasculares ao estresse emocíonal. A inibição dos neurônios dessa área reduz os aumentos de freqüência cardíaca e de pressão arterial em ratos quando submetidos à situações de estresse emocional. Ao contrário, a ativação farmacológica dos neurônios do DMH produz aumento na frequência cardíaca, pressão arterial, hormônio adrenocorticotrópico (ACTH), atividade locomotora e na atividade simpática para diversos leitos vasculares. A similaridade dessa resposta com aquela produzida durante a situação real de estresse emocíonal sugere que esta área é fundamental na integração da resposta fisiológica ao estresse.A presente revisão tem como objetivo mostrar, através de resultados de estudos recentes, as vias centrais utilizadas pelo DMH na organização da resposta cardiovascular ao estresse emocional.